You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Sapropterin treatment does not enhance the health‐related quality of life of patients with phenylketonuria and their parents
Contributor:
Feldmann, Reinhold;
Wolfgart, Eva;
Weglage, Josef;
Rutsch, Frank
Published:
Wiley, 2017
Published in:
Acta Paediatrica, 106 (2017) 6, Seite 953-959
Language:
English
DOI:
10.1111/apa.13799
ISSN:
0803-5253;
1651-2227
Origination:
Footnote:
Description:
AbstractAimSapropterin causes reductions in blood phenylalanine concentrations in sensitive patients with phenylketonuria (PKU). We examined whether the subsequent relaxation of dietary restrictions influenced the quality of life (QoL) of patients and parents.MethodsThe study cohort comprised 112 patients with PKU followed at the metabolic centre at Münster University Children's Hospital, Germany, from 2012 to 2015. A sapropterin response was defined as a ≥30% reduction in blood phenylalanine levels. The QoL of 38 children and adolescents from the study cohort, with a mean age of 12.4 (range 6.6–18.7) years, was assessed in an outpatient setting and 49 parents of children with PKU also commented on their child's QoL and their own. The participants’ QoL was assessed before the start of therapy, and again after six months, using self‐report questionnaires.ResultsAfter six months of continuous therapy or diet, QoL was largely unchanged in the patients, according to their self‐reports and the parental reports. QoL also remained unchanged in the parents.ConclusionSapropterin did not seem to improve QoL in PKU patients and their parents. Patients with PKU had already reached high levels of QoL following classic diets, and these levels were not easily improved by sapropterin.